Acute hepatitis has a broad range of etiologies that consist of viral infection, autoimmune disease, toxic, and metabolic disorders. Hepatitis E virus (HEV) is the second most common cause of sporadic hepatitis in the Middle East and North Africa with the highest incidence in Asia, Africa, Middle East, and Central America ([@CIT0001], [@CIT0002]). HEV is an icosahedral, non-enveloped single-stranded RNA virus, that is, approximately 27--34 nm in diameter. HEV has four genotypes. In developed countries, sporadic cases of HEV genotype 3 have occurred following consumption of uncooked/undercooked pork or deer meat ([@CIT0002]), whereas in developing countries like India and Bangladesh, the burden of HEV infection is from HEV genotype 1 and 2 ([@CIT0003]). Diagnosis of acute hepatitis E is made based on detection of HEV RNA by polymerase chain reaction (PCR) and/or anti-HEV IgM. During the resolution phase of the infection, serum is positive for anti-HEV IgG. HEV infection is usually a self-limiting disease in immunocompetent patients. HEV is associated with acute liver failure ([@CIT0004]) and in some cases is thought to trigger possibly an immune response that can ultimately develop into autoimmune hepatitis (AIH) ([@CIT0005]). We present a case of new onset jaundice and markedly elevated transaminases suggestive of AIH but found to be acute HEV infection.

Case presentation {#S0002}
=================

A 32-year-old overweight non-alcoholic non-smoker Bengali man was admitted to our hospital with jaundice, nausea, non-bilious, non-bloody vomiting, and worsening malaise for 3 days. His past medical history was significant for type 2 diabetes mellitus, hypertension, and hyperlipidemia. He denied any sick contacts, use of herbs, or recent change in medications. His physical examination was significant for normal vital signs, scleral icterus, and without stigmata for chronic liver disease. Laboratory values on admission and during the hospital course are shown in [Table 1](#T0001){ref-type="table"}. In our patient, initial workup revealed alkaline phosphatase (ALP)/aspartate transaminase (AST) with ratio \<1.5, more than twofold increase in IgG, antinuclear antibody (ANA), and anti-smooth muscle antibody (ASMA) titer \>1:80, anti-mitochondrial antibody (AMA) positive, negative drug history, and no alcohol intake. A liver biopsy performed showed lymphoplasmacytic portal inflammation with significant interface hepatitis and cholestasis ([Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). These clinical findings added up to an International Autoimmune Hepatitis Group (IAIHG) score of 13 points. Because the patient emigrated from an endemic area for hepatitis E about 1 month prior to presentation, HEV IgM was checked, which subsequently returned positive. The test was performed by Focus Diagnostics, Inc. based out of San Juan Capistrano, CA, using enzyme linked immunosorbent assay method. The patient was treated with supportive care and closely monitored in an outpatient clinic. He improved clinically with significant improvement of his liver function tests over the next month.
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###### 

Laboratory values

                      Day 1            Day 2   Day 8            Day 9   Day 11   Day 27
  ------------------- ---------------- ------- ---------------- ------- -------- --------
  WBC (K/mcl)         7.9                      8.6                               5.3
  Platelets (K/mcl)   168                      276                               214
  AST (U/L)           642              573     346              227     97       33
  ALT (U/L)           1,249            1,096   1,082            797     378      38
  ALP                 152              148     138              121     94       76
  GGT                 235              203     109              93      74       45
  LDH                 419              396     221              160     126      155
  Albumin             4.0              3.6     4.1              3.7     3.2      4.1
  Total bilirubin     5.1              5.4     12.1             10.9    8.0      1.2
  Conj. bilirubin     3.1              3.2     7.2              6.7     4.5      0.6
  INR                                  1.2     1.1                               
  PT                                   13.3    11.6                              
  IgG                                                           3,590            2,330
  IgA                                                           318              233
  IgM                                                           199              148
  HAV IgM             Negative                                                   
  HBsAg               Negative                                                   
  HBsAb               Negative                                                   
  HBcAb               Negative                                                   
  HEV IgM                                      Positive                          
  HCV RNA PCR         Not detectable                                             
  HSV DNA PCR                                  Not detectable                    
  CMV DNA PCR                                  Not detectable                    
  HIV                 Negative                                                   
  ANA                 1:1,280                                                    
  ASMA                1:160                                                      
  AMA                 1:40                                                       

Discussion {#S0003}
==========

IAIHG developed a diagnostic scoring system, which outlined 13 criteria for the diagnosis of AIH in a majority of the patients. It included gender; ALP to AST or alanine transaminase (ALT) ratio; serum globulins or IgG levels; ANA, ASMA, or anti-liver-kidney microsome antibodies; AMA; hepatitis viral markers; drug history; average alcohol intake; liver histology; other autoimmune diseases; seropositivity for other defined autoantibodies; HLA DR3 or DR4; and response to therapy ([@CIT0006]).

In our case, the IAIHG score of 13 points meets the criteria for 'probable AIH'. Concomitantly, he was positive for anti-HEV IgM and IgG antibodies suggesting acute HEV infection. The pathophysiology of these concomitant presentations of AIH and HEV seroprevalence is not well understood. Several studies have reported the presence of anti-HEV IgG antibodies in patients with AIH suggesting that HEV infection may act as a possible trigger or hapten for the development of AIH ([@CIT0005]). Similar to our case, AMA is found to be present in sera of patients with AIH more frequently than expected. However, the clinical significance of it remains unclear ([@CIT0007]).

Several observations in our case suggest that HEV may have triggered an AIH response. Resolution of abnormal liver function test and clinical recovery in a short period of 6--8 weeks without any intervention is unlikely in patient with AIH ([@CIT0008]). Liver biopsy showing signs of portal inflammation and cholestasis is characteristic of viral etiology. Serology tests were positive for HEV. Patient clinically improved and returned to his home country. Due to that, we were not able to send HEV PCR. HEV PCR is considered to be the most sensitive test for diagnosing acute HEV infection. However, a recent investigation showed a variable sensitivity for different HEV PCR assays ([@CIT0009]). Similar cases with a concomitant presentation of HEV and autoimmune mimicry have been reported in the literature ([@CIT0010], [@CIT0011]).

This case illustrates the importance of excluding acute HEV in patients with criteria for 'probable AIH' from an endemic area. Empiric therapy for AIH may lead to protracted and unnecessary therapy. Effect of steroids in such cases, beneficial or harmful, is unclear given the paucity of data in the literature.

In conclusion, our case is unique as it shows that in-patients who are clinically stable and improving with conservative management, treatment with steroids should be delayed until HEV is appropriately ruled out.
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